HEADER TRANSFERASE 30-NOV-22 8HLJ
TITLE MUTATED HUMAN ADP-RIBOSYLTRANSFERASE 2 (PARP2) CATALYTIC DOMAIN BOUND
TITLE 2 TO OLAPARIB (AZD2281)
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: POLY [ADP-RIBOSE] POLYMERASE 2;
COMPND 3 CHAIN: A, B;
COMPND 4 SYNONYM: PARP-2,HPARP-2,ADP-RIBOSYLTRANSFERASE DIPHTHERIA TOXIN-LIKE
COMPND 5 2,ARTD2,DNA ADP-RIBOSYLTRANSFERASE PARP2,NAD(+) ADP-
COMPND 6 RIBOSYLTRANSFERASE 2,ADPRT-2,POLY[ADP-RIBOSE] SYNTHASE 2,PADPRT-2,
COMPND 7 PROTEIN POLY-ADP-RIBOSYLTRANSFERASE PARP2;
COMPND 8 EC: 2.4.2.30,2.4.2.-;
COMPND 9 ENGINEERED: YES;
COMPND 10 MUTATION: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 ORGANISM_TAXID: 9606;
SOURCE 5 GENE: PARP2, ADPRT2, ADPRTL2;
SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI;
SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562
KEYWDS DNA ADP-RIBOSYLTRANSFERASE 2, PARP2, OLAPARIB, AZD2281, TRANSFERASE
EXPDTA X-RAY DIFFRACTION
AUTHOR X.Y.WANG,J.ZHOU,B.L.XU
REVDAT 1 01-MAY-24 8HLJ 0
JRNL AUTH X.Y.WANG,J.ZHOU,B.L.XU
JRNL TITL MUTATED HUMAN ADP-RIBOSYLTRANSFERASE 2 (PARP2) CATALYTIC
JRNL TITL 2 DOMAIN BOUND TO OLAPARIB (AZD2281)
JRNL REF TO BE PUBLISHED
JRNL REFN
REMARK 2
REMARK 2 RESOLUTION. 2.24 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : PHENIX 1.20.1_4487
REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN
REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE,
REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER,
REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY,
REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON,
REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI,
REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT
REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART
REMARK 3
REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.24
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.91
REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350
REMARK 3 COMPLETENESS FOR RANGE (%) : 99.4
REMARK 3 NUMBER OF REFLECTIONS : 31971
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 R VALUE (WORKING + TEST SET) : 0.202
REMARK 3 R VALUE (WORKING SET) : 0.200
REMARK 3 FREE R VALUE : 0.247
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.810
REMARK 3 FREE R VALUE TEST SET COUNT : 1538
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS).
REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE
REMARK 3 1 47.9100 - 4.9800 0.99 2812 153 0.1641 0.1896
REMARK 3 2 4.9800 - 3.9500 1.00 2799 146 0.1545 0.1891
REMARK 3 3 3.9500 - 3.4500 1.00 2788 140 0.1731 0.2124
REMARK 3 4 3.4500 - 3.1400 1.00 2752 149 0.2099 0.2577
REMARK 3 5 3.1400 - 2.9100 1.00 2787 137 0.2243 0.3240
REMARK 3 6 2.9100 - 2.7400 1.00 2766 143 0.2404 0.2911
REMARK 3 7 2.7400 - 2.6000 1.00 2811 116 0.2469 0.3212
REMARK 3 8 2.6000 - 2.4900 1.00 2803 131 0.2546 0.3064
REMARK 3 9 2.4900 - 2.3900 1.00 2739 139 0.2713 0.3319
REMARK 3 10 2.3900 - 2.3100 1.00 2763 156 0.2784 0.3753
REMARK 3 11 2.3100 - 2.2400 0.94 2613 128 0.2777 0.3399
REMARK 3
REMARK 3 BULK SOLVENT MODELLING.
REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL
REMARK 3 SOLVENT RADIUS : 1.10
REMARK 3 SHRINKAGE RADIUS : 0.90
REMARK 3 K_SOL : NULL
REMARK 3 B_SOL : NULL
REMARK 3
REMARK 3 ERROR ESTIMATES.
REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.290
REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.788
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : 36.18
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.21
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : NULL
REMARK 3 B22 (A**2) : NULL
REMARK 3 B33 (A**2) : NULL
REMARK 3 B12 (A**2) : NULL
REMARK 3 B13 (A**2) : NULL
REMARK 3 B23 (A**2) : NULL
REMARK 3
REMARK 3 TWINNING INFORMATION.
REMARK 3 FRACTION: NULL
REMARK 3 OPERATOR: NULL
REMARK 3
REMARK 3 DEVIATIONS FROM IDEAL VALUES.
REMARK 3 RMSD COUNT
REMARK 3 BOND : 0.004 5762
REMARK 3 ANGLE : 0.745 7783
REMARK 3 CHIRALITY : 0.045 842
REMARK 3 PLANARITY : 0.005 1001
REMARK 3 DIHEDRAL : 18.763 2188
REMARK 3
REMARK 3 TLS DETAILS
REMARK 3 NUMBER OF TLS GROUPS : NULL
REMARK 3
REMARK 3 NCS DETAILS
REMARK 3 NUMBER OF NCS GROUPS : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 8HLJ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBC ON 08-DEC-22.
REMARK 100 THE DEPOSITION ID IS D_1300033821.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 22-MAY-23
REMARK 200 TEMPERATURE (KELVIN) : 100
REMARK 200 PH : NULL
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : SSRF
REMARK 200 BEAMLINE : BL02U1
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 0.979183
REMARK 200 MONOCHROMATOR : NULL
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : PIXEL
REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL
REMARK 200 DATA SCALING SOFTWARE : AIMLESS
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 31971
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.240
REMARK 200 RESOLUTION RANGE LOW (A) : 47.910
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4
REMARK 200 DATA REDUNDANCY : 6.400
REMARK 200 R MERGE (I) : NULL
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 17.9300
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.24
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.32
REMARK 200 COMPLETENESS FOR SHELL (%) : NULL
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : NULL
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: MOLREP
REMARK 200 STARTING MODEL: ALPHAFOLD MODEL
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 41.85
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.12
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: 25% PEG-3350, 0.1 M TRIS-HCL PH 8.5,
REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 296.5K
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X,Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 43.14400
REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1, 2
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 350
REMARK 350 BIOMOLECULE: 2
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: B
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 GLY A 229
REMARK 465 LEU A 580
REMARK 465 GLN A 581
REMARK 465 GLN B 581
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 ARG A 351 -160.32 -104.07
REMARK 500 GLN A 352 -128.61 -118.68
REMARK 500 HIS A 394 62.41 -108.15
REMARK 500 LYS A 480 71.76 -115.23
REMARK 500 ASN A 502 100.96 -166.73
REMARK 500 GLN A 510 71.21 29.96
REMARK 500 VAL A 529 -168.79 -128.67
REMARK 500 LEU A 538 -161.70 -73.10
REMARK 500 ARG A 570 -51.90 -128.10
REMARK 500 ASN B 247 98.72 -69.70
REMARK 500 ARG B 322 -38.43 -134.44
REMARK 500 ARG B 351 -99.50 -74.80
REMARK 500 GLN B 352 -151.93 -174.00
REMARK 500 HIS B 394 65.26 -112.45
REMARK 500 ARG B 417 84.64 -69.27
REMARK 500 LYS B 480 77.96 -104.36
REMARK 500 ASN B 502 98.92 -163.19
REMARK 500 GLN B 510 39.36 31.63
REMARK 500 PRO B 537 72.30 -69.91
REMARK 500 THR B 544 54.34 -94.98
REMARK 500 PRO B 549 49.67 -73.21
REMARK 500 ASP B 550 -87.70 -119.52
REMARK 500
REMARK 500 REMARK: NULL
DBREF 8HLJ A 230 581 UNP Q9UGN5 PARP2_HUMAN 230 581
DBREF 8HLJ B 230 581 UNP Q9UGN5 PARP2_HUMAN 230 581
SEQADV 8HLJ GLY A 229 UNP Q9UGN5 EXPRESSION TAG
SEQADV 8HLJ SER A 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION
SEQADV 8HLJ ARG A 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION
SEQADV 8HLJ GLY A 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION
SEQADV 8HLJ LEU A 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION
SEQADV 8HLJ GLY B 229 UNP Q9UGN5 EXPRESSION TAG
SEQADV 8HLJ SER B 349 UNP Q9UGN5 THR 349 ENGINEERED MUTATION
SEQADV 8HLJ ARG B 351 UNP Q9UGN5 LEU 351 ENGINEERED MUTATION
SEQADV 8HLJ GLY B 353 UNP Q9UGN5 SER 353 ENGINEERED MUTATION
SEQADV 8HLJ LEU B 354 UNP Q9UGN5 PRO 354 ENGINEERED MUTATION
SEQRES 1 A 353 GLY PRO GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU
SEQRES 2 A 353 ILE LYS LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET
SEQRES 3 A 353 MET MET GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU
SEQRES 4 A 353 GLY LYS LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN
SEQRES 5 A 353 SER LEU LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN
SEQRES 6 A 353 HIS GLY ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR
SEQRES 7 A 353 THR ARG ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO
SEQRES 8 A 353 LEU ILE ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN
SEQRES 9 A 353 LEU LEU GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS
SEQRES 10 A 353 LEU VAL LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU
SEQRES 11 A 353 ASP GLN HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO
SEQRES 12 A 353 LEU ASP HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN
SEQRES 13 A 353 TYR LEU GLN SER THR HIS ALA PRO THR HIS SER ASP TYR
SEQRES 14 A 353 THR MET THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP
SEQRES 15 A 353 GLY GLU LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG
SEQRES 16 A 353 MET LEU LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL
SEQRES 17 A 353 GLY ILE LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU
SEQRES 18 A 353 ALA PRO ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR
SEQRES 19 A 353 PHE ALA ASP MET SER SER LYS SER ALA ASN TYR CYS PHE
SEQRES 20 A 353 ALA SER ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER
SEQRES 21 A 353 GLU VAL ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA
SEQRES 22 A 353 ASN PRO LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER
SEQRES 23 A 353 THR LYS GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS
SEQRES 24 A 353 PHE VAL THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO
SEQRES 25 A 353 ALA SER ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR
SEQRES 26 A 353 LEU ASN TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN
SEQRES 27 A 353 VAL ARG MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE
SEQRES 28 A 353 LEU GLN
SEQRES 1 B 353 GLY PRO GLU SER GLN LEU ASP LEU ARG VAL GLN GLU LEU
SEQRES 2 B 353 ILE LYS LEU ILE CYS ASN VAL GLN ALA MET GLU GLU MET
SEQRES 3 B 353 MET MET GLU MET LYS TYR ASN THR LYS LYS ALA PRO LEU
SEQRES 4 B 353 GLY LYS LEU THR VAL ALA GLN ILE LYS ALA GLY TYR GLN
SEQRES 5 B 353 SER LEU LYS LYS ILE GLU ASP CYS ILE ARG ALA GLY GLN
SEQRES 6 B 353 HIS GLY ARG ALA LEU MET GLU ALA CYS ASN GLU PHE TYR
SEQRES 7 B 353 THR ARG ILE PRO HIS ASP PHE GLY LEU ARG THR PRO PRO
SEQRES 8 B 353 LEU ILE ARG THR GLN LYS GLU LEU SER GLU LYS ILE GLN
SEQRES 9 B 353 LEU LEU GLU ALA LEU GLY ASP ILE GLU ILE ALA ILE LYS
SEQRES 10 B 353 LEU VAL LYS SER GLU ARG GLN GLY LEU GLU HIS PRO LEU
SEQRES 11 B 353 ASP GLN HIS TYR ARG ASN LEU HIS CYS ALA LEU ARG PRO
SEQRES 12 B 353 LEU ASP HIS GLU SER TYR GLU PHE LYS VAL ILE SER GLN
SEQRES 13 B 353 TYR LEU GLN SER THR HIS ALA PRO THR HIS SER ASP TYR
SEQRES 14 B 353 THR MET THR LEU LEU ASP LEU PHE GLU VAL GLU LYS ASP
SEQRES 15 B 353 GLY GLU LYS GLU ALA PHE ARG GLU ASP LEU HIS ASN ARG
SEQRES 16 B 353 MET LEU LEU TRP HIS GLY SER ARG MET SER ASN TRP VAL
SEQRES 17 B 353 GLY ILE LEU SER HIS GLY LEU ARG ILE ALA PRO PRO GLU
SEQRES 18 B 353 ALA PRO ILE THR GLY TYR MET PHE GLY LYS GLY ILE TYR
SEQRES 19 B 353 PHE ALA ASP MET SER SER LYS SER ALA ASN TYR CYS PHE
SEQRES 20 B 353 ALA SER ARG LEU LYS ASN THR GLY LEU LEU LEU LEU SER
SEQRES 21 B 353 GLU VAL ALA LEU GLY GLN CYS ASN GLU LEU LEU GLU ALA
SEQRES 22 B 353 ASN PRO LYS ALA GLU GLY LEU LEU GLN GLY LYS HIS SER
SEQRES 23 B 353 THR LYS GLY LEU GLY LYS MET ALA PRO SER SER ALA HIS
SEQRES 24 B 353 PHE VAL THR LEU ASN GLY SER THR VAL PRO LEU GLY PRO
SEQRES 25 B 353 ALA SER ASP THR GLY ILE LEU ASN PRO ASP GLY TYR THR
SEQRES 26 B 353 LEU ASN TYR ASN GLU TYR ILE VAL TYR ASN PRO ASN GLN
SEQRES 27 B 353 VAL ARG MET ARG TYR LEU LEU LYS VAL GLN PHE ASN PHE
SEQRES 28 B 353 LEU GLN
HET 09L A 601 32
HET 09L B 601 32
HETNAM 09L 4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-
HETNAM 2 09L 4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
HETSYN 09L OLAPARIB
FORMUL 3 09L 2(C24 H23 F N4 O3)
FORMUL 5 HOH *183(H2 O)
HELIX 1 AA1 ASP A 235 CYS A 246 1 12
HELIX 2 AA2 ASN A 247 MET A 258 1 12
HELIX 3 AA3 PRO A 266 LEU A 270 5 5
HELIX 4 AA4 THR A 271 ALA A 291 1 21
HELIX 5 AA5 GLY A 295 ILE A 309 1 15
HELIX 6 AA6 THR A 323 SER A 349 1 27
HELIX 7 AA7 HIS A 356 HIS A 366 1 11
HELIX 8 AA8 SER A 376 THR A 389 1 14
HELIX 9 AA9 GLY A 411 PHE A 416 1 6
HELIX 10 AB1 ARG A 431 SER A 433 5 3
HELIX 11 AB2 ASN A 434 GLY A 442 1 9
HELIX 12 AB3 PRO A 451 TYR A 455 5 5
HELIX 13 AB4 MET A 466 ASN A 472 1 7
HELIX 14 AB5 TYR A 473 PHE A 475 5 3
HELIX 15 AB6 ASN A 563 ASN A 565 5 3
HELIX 16 AB7 ASP B 235 CYS B 246 1 12
HELIX 17 AB8 ASN B 247 MET B 258 1 12
HELIX 18 AB9 PRO B 266 LEU B 270 5 5
HELIX 19 AC1 THR B 271 ALA B 291 1 21
HELIX 20 AC2 GLY B 295 ILE B 309 1 15
HELIX 21 AC3 THR B 323 SER B 349 1 27
HELIX 22 AC4 HIS B 356 HIS B 366 1 11
HELIX 23 AC5 SER B 376 THR B 389 1 14
HELIX 24 AC6 GLY B 411 PHE B 416 1 6
HELIX 25 AC7 ARG B 431 SER B 433 5 3
HELIX 26 AC8 ASN B 434 GLY B 442 1 9
HELIX 27 AC9 PRO B 451 TYR B 455 5 5
HELIX 28 AD1 MET B 466 ASN B 472 1 7
HELIX 29 AD2 TYR B 473 PHE B 475 5 3
HELIX 30 AD3 LYS B 504 LEU B 509 5 6
HELIX 31 AD4 SER B 525 PHE B 528 5 4
HELIX 32 AD5 ASN B 563 ASN B 565 5 3
SHEET 1 AA1 5 CYS A 367 PRO A 371 0
SHEET 2 AA1 5 THR A 398 LYS A 409 -1 O GLU A 406 N ARG A 370
SHEET 3 AA1 5 VAL A 567 ASN A 578 -1 O ARG A 570 N VAL A 407
SHEET 4 AA1 5 THR A 482 ALA A 491 -1 N LEU A 485 O LEU A 573
SHEET 5 AA1 5 ARG A 423 GLY A 429 -1 N HIS A 428 O LEU A 486
SHEET 1 AA2 4 ILE A 461 PHE A 463 0
SHEET 2 AA2 4 GLU A 558 VAL A 561 -1 O VAL A 561 N ILE A 461
SHEET 3 AA2 4 SER A 514 GLY A 517 -1 N GLY A 517 O GLU A 558
SHEET 4 AA2 4 CYS A 495 LEU A 498 1 N ASN A 496 O SER A 514
SHEET 1 AA3 3 ALA A 541 ASP A 543 0
SHEET 2 AA3 3 GLY A 519 PRO A 523 -1 N ALA A 522 O SER A 542
SHEET 3 AA3 3 LEU A 554 TYR A 556 1 O LEU A 554 N LYS A 520
SHEET 1 AA4 2 VAL A 529 LEU A 531 0
SHEET 2 AA4 2 SER A 534 VAL A 536 -1 O SER A 534 N LEU A 531
SHEET 1 AA5 5 CYS B 367 PRO B 371 0
SHEET 2 AA5 5 TYR B 397 LYS B 409 -1 O GLU B 406 N ARG B 370
SHEET 3 AA5 5 VAL B 567 PHE B 579 -1 O ARG B 570 N VAL B 407
SHEET 4 AA5 5 THR B 482 ALA B 491 -1 N LEU B 485 O LEU B 573
SHEET 5 AA5 5 ARG B 423 GLY B 429 -1 N MET B 424 O VAL B 490
SHEET 1 AA6 4 ILE B 461 PHE B 463 0
SHEET 2 AA6 4 GLU B 558 VAL B 561 -1 O TYR B 559 N PHE B 463
SHEET 3 AA6 4 SER B 514 GLY B 517 -1 N THR B 515 O ILE B 560
SHEET 4 AA6 4 CYS B 495 LEU B 498 1 N LEU B 498 O LYS B 516
SHEET 1 AA7 3 ALA B 541 ASP B 543 0
SHEET 2 AA7 3 GLY B 519 PRO B 523 -1 N ALA B 522 O SER B 542
SHEET 3 AA7 3 LEU B 554 TYR B 556 1 O ASN B 555 N MET B 521
SHEET 1 AA8 2 VAL B 529 LEU B 531 0
SHEET 2 AA8 2 SER B 534 VAL B 536 -1 O SER B 534 N LEU B 531
CRYST1 40.902 86.288 95.828 90.00 90.44 90.00 P 1 21 1 4
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.024449 0.000000 0.000188 0.00000
SCALE2 0.000000 0.011589 0.000000 0.00000
SCALE3 0.000000 0.000000 0.010436 0.00000